228 related articles for article (PubMed ID: 20170101)
1. A computational approach to the study of the binding mode of dual ACE/NEP inhibitors.
Dimitropoulos N; Papakyriakou A; Dalkas GA; Sturrock ED; Spyroulias GA
J Chem Inf Model; 2010 Mar; 50(3):388-96. PubMed ID: 20170101
[TBL] [Abstract][Full Text] [Related]
2. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC
J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.
Olimpieri F; Tambaro S; Fustero S; Lazzari P; Sanchez-Roselló M; Pani L; Volonterio A; Zanda M
Bioorg Med Chem Lett; 2009 Aug; 19(16):4715-9. PubMed ID: 19596577
[TBL] [Abstract][Full Text] [Related]
4. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain.
Georgiadis D; Cuniasse P; Cotton J; Yiotakis A; Dive V
Biochemistry; 2004 Jun; 43(25):8048-54. PubMed ID: 15209500
[TBL] [Abstract][Full Text] [Related]
5. Novel ketomethylene inhibitors of angiotensin I-converting enzyme (ACE): inhibition and molecular modelling.
Redelinghuys P; Nchinda AT; Chibale K; Sturrock ED
Biol Chem; 2006 Apr; 387(4):461-6. PubMed ID: 16606345
[TBL] [Abstract][Full Text] [Related]
6. Simulated interactions between angiotensin-converting enzyme and substrate gonadotropin-releasing hormone: novel insights into domain selectivity.
Papakyriakou A; Spyroulias GA; Sturrock ED; Manessi-Zoupa E; Cordopatis P
Biochemistry; 2007 Jul; 46(30):8753-65. PubMed ID: 17605472
[TBL] [Abstract][Full Text] [Related]
7. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
[TBL] [Abstract][Full Text] [Related]
8. Screening of selected basidiomycetes for inhibitory activity on neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE).
Melzig MF; Pieper S; Siems WE; Heder G; Bóttger A; Liberra K; Lindequist U
Pharmazie; 1996 Jul; 51(7):501-3. PubMed ID: 8774843
[TBL] [Abstract][Full Text] [Related]
9. Domain-selective ligand-binding modes and atomic level pharmacophore refinement in angiotensin I converting enzyme (ACE) inhibitors.
Tzakos AG; Gerothanassis IP
Chembiochem; 2005 Jun; 6(6):1089-103. PubMed ID: 15883972
[TBL] [Abstract][Full Text] [Related]
10. Development of domain-selective angiotensin I-converting enzyme inhibitors.
Redelinghuys P; Nchinda AT; Sturrock ED
Ann N Y Acad Sci; 2005 Nov; 1056():160-75. PubMed ID: 16387685
[TBL] [Abstract][Full Text] [Related]
11. Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides.
Robl JA; Sulsky R; Sieber-McMaster E; Ryono DE; Cimarusti MP; Simpkins LM; Karanewsky DS; Chao S; Asaad MM; Seymour AA; Fox M; Smith PL; Trippodo NC
J Med Chem; 1999 Jan; 42(2):305-11. PubMed ID: 9925736
[TBL] [Abstract][Full Text] [Related]
12. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
[TBL] [Abstract][Full Text] [Related]
13. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Fink CA; Carlson JE; McTaggart PA; Qiao Y; Webb R; Chatelain R; Jeng AY; Trapani AJ
J Med Chem; 1996 Aug; 39(16):3158-68. PubMed ID: 8759637
[TBL] [Abstract][Full Text] [Related]
14. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
Krum H; Gilbert RE
J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
[TBL] [Abstract][Full Text] [Related]
15. Combined use of selective inhibitors and fluorogenic substrates to study the specificity of somatic wild-type angiotensin-converting enzyme.
Jullien ND; Cuniasse P; Georgiadis D; Yiotakis A; Dive V
FEBS J; 2006 Apr; 273(8):1772-81. PubMed ID: 16623712
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase.
French JF; Flynn GA; Giroux EL; Mehdi S; Anderson B; Beach DC; Koehl JR; Dage RC
J Pharmacol Exp Ther; 1994 Jan; 268(1):180-6. PubMed ID: 8301555
[TBL] [Abstract][Full Text] [Related]
17. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme.
Nchinda AT; Chibale K; Redelinghuys P; Sturrock ED
Bioorg Med Chem Lett; 2006 Sep; 16(17):4616-9. PubMed ID: 16784843
[TBL] [Abstract][Full Text] [Related]
19. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
Roques BP
Pathol Biol (Paris); 1998 Mar; 46(3):191-200. PubMed ID: 9769915
[TBL] [Abstract][Full Text] [Related]
20. The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme.
Sharma RK; Espinoza-Moraga M; Poblete H; Douglas RG; Sturrock ED; Caballero J; Chibale K
J Chem Inf Model; 2016 Dec; 56(12):2486-2494. PubMed ID: 27959521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]